Drugs for Visceral Steatosis, Congenital (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 39)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Amlodipine |
Approved |
Phase 4 |
|
88150-42-9 |
2162 |
Synonyms:
()-Amlodipine
(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)
-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine
3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl ( -)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat
3-Ethyl-5-methyl ( -)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid
3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
88150-42-9
88150-47-4 (maleate (1:1))
AC1L1D26
AC1Q32ZS
AC-4535
Almirall brand OF amlodipine besilate
Ambap88150-42-9
Amlocard
amlodipine
Amlodipine
Amlodipine (INN)
Amlodipine [INN:BAN]
AMLODIPINE BASE
Amlodipine Benzenesulfonate
Amlodipine besilate
Amlodipine Besilate
Amlodipine besylate
Amlodipine Besylate
Amlodipine free base
Amlodipine Free Base
Amlodipine maleate
Amlodipine maleate (1:1)
Amlodipine, (+-)-isomer
Amlodipine, (+-)-isomer, maleate (1:1)
Amlodipine, (R)-isomer
Amlodipine, (S)-isomer, maleate (1:1)
Amlodipino
Amlodipino [Spanish]
Amlodipinum
Amlodipinum [Latin]
Amlodis
Amlopres
Amlor
|
Amvaz
AMVAZ
Astudal
BIDD:GT0810
BRD-A22032524-074-02-4
BRD-A22032524-074-03-2
BSPBio_002727
C06825
CHEBI:2668
CHEMBL1491
CID2162
Coroval
CPD000469198
D07450
DB00381
Eczacibasi brand OF amlodipine besilate
HMS2052N03
HMS2089H07
I14-0798
Intervask
Istin
KBio3_001947
KBioGR_001643
Lipinox
Lotrel
LS-131183
Mack brand OF amlodipine besilate
MLS001401409
MolPort-001-792-963
NCGC00165957-01
NCGC00165957-02
NCGC00165957-03
Norvasc
Norvasc (TN)
Pelmec
Pfizer brand OF amlodipine besilate
R,S)-Amlodipine
Racemic amlodipine
Racemic Amlodipine
SAM001246705
SMR000469198
SPBio_000351
Spectrum2_000486
Spectrum3_001004
Spectrum4_001132
Spectrum5_001550
UK-4834011
UNII-1J444QC288
|
|
2 |
|
Angiotensin II |
Approved, Investigational |
Phase 4 |
|
68521-88-0, 4474-91-3, 11128-99-7 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-isoleucine-angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-isoleucineangiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
|
Angiotonin
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
3 |
|
Simvastatin |
Approved |
Phase 4 |
|
79902-63-9 |
54454 |
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
Bio-0672
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
Cholestat
CID54454
Coledis
Colemin
Corolin
CPD000718785
D00434
D019821
Denan
DivK1c_006991
DRG-0320
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
Kolestevan
KS-1113
L 644128-000U
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
LS-46264
Medipo
MK 0733
MK 733
MK-0733
MK733
MK-733
|
MLS001304029
MLS001333077
MLS001333078
MLS002154038
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
nchembio790-comp16
Nivelipol
Nor-vastina
Pantok
Pepstatin
Prestwick_171
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
Simcor
Simovil
Simvast CR
simvastatin
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [Usan:Ban:Inn]
Simvastatin [USAN:INN:BAN]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SMR000718785
SPBio_001881
SPBio_002830
SpecPlus_000895
Spectrum_001717
SPECTRUM1504236
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Statin
STK801938
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
|
|
4 |
|
Losartan |
Approved |
Phase 4 |
|
114798-26-4 |
3961 |
Synonyms:
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
114798-26-4
124750-99-8 (mono-potassium salt)
1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol
2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol
2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole
AC1L1H3Q
BIDD:GT0286
BRD-K76205745-001-02-5
BSPBio_002695
C07072
C22H23ClN6O
CHEBI:6541
CHEMBL191
CID3961
CL23623
Cozaar
D08146
DB00678
DuP 753
DUP 89
DuP-753
HMS1922J13
HMS2093E22
Hyzaar
I14-9710
Jsp001094
KBio2_002193
KBio2_004761
|
KBio2_007329
KBio3_001915
KBioGR_001611
KBioSS_002193
L000351
Lortaan
losartan
Losartan
Losartan (INN)
Losartan [INN:BAN]
Losartan monopotassium salt
losartan potassium
Losartan potassium
LOSARTAN POTASSIUM
Losartic
Losartic (TN)
LS-78746
MK954
MK-954
MolPort-003-666-553
Monopotassium salt, losartan
NCGC00095125-01
NCGC00095125-02
NCGC00095125-03
Oprea1_644635
Potassium, losartan
Salt, losartan monopotassium
SPBio_001893
Spectrum_001713
SPECTRUM1504268
Spectrum2_001677
Spectrum3_000998
Spectrum4_001126
Spectrum5_001466
UNII-JMS50MPO89
|
|
5 |
|
Efavirenz |
Approved, Investigational |
Phase 4 |
|
154598-52-4 |
64139 |
Synonyms:
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-Efavirenz
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
154598-52-4
1ikv
1ikw
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
6-Chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
AC-19049
AC1L20IX
BIDD:GT0383
Bristol-myers squibb brand OF efavirenz
C08088
C14H9ClF3NO2
CHEBI:119486
CHEMBL223228
CID64139
CPD000466351
D00896
DB00625
DB07709
DMP 266
DMP-266
Du pont brand OF efavirenz
efavirenz
Efavirenz
|
Éfavirenz
Efavirenz (JAN/INN)
Efavirenz, (R)-isomer
efavirenz, (S)-isomer
Efavirenz, (S)-isomer
Efavirenzum
EFV
EFZ
Eravirenz
HMS2051J08
HMS2090N16
HSDB 7163
L 743726
L-741211
L-743,726
L-743725
L-743726
LS-173464
Merck sharp and dohme brand OF efavirenz
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MLS000759465
MLS001424087
MolPort-003-983-924
NSC742403
SAM001246667
SBB066062
SMR000466351
Stocrin
Strocin (TM)
Sustiva
Sustiva (TM)
Sustiva (TN)
UNII-JE6H2O27P8
United drug brand OF efavirenz
ZINC02020233
zoxazin-2-one
|
|
6 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4 |
|
|
|
7 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
8 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
9 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
10 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
11 |
|
Hormones |
|
Phase 4 |
|
|
|
12 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
13 |
|
Angiotensinogen |
|
Phase 4 |
|
|
|
14 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
15 |
|
Giapreza |
|
Phase 4 |
|
|
|
16 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 4 |
|
|
|
17 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
18 |
|
Angiotensin Receptor Antagonists |
|
Phase 4 |
|
|
|
19 |
|
calcium channel blockers |
|
Phase 4 |
|
|
|
20 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
21 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
22 |
|
Anti-HIV Agents |
|
Phase 4 |
|
|
|
23 |
|
Raltegravir Potassium |
|
Phase 4 |
|
|
|
24 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
25 |
|
Reverse Transcriptase Inhibitors |
|
Phase 4 |
|
|
|
26 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
27 |
|
HIV Integrase Inhibitors |
|
Phase 4 |
|
|
|
28 |
|
Anti-Retroviral Agents |
|
Phase 4 |
|
|
|
29 |
|
Integrase Inhibitors |
|
Phase 4 |
|
|
|
30 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
31 |
|
Metformin |
Approved |
|
|
657-24-9 |
14219 4091 |
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
cMAP_000016
D04966
DB00331
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMGG
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
Haurymelin
HMS2089D19
HSCI1_000295
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
|
KBioSS_002312
LA-6023
LS-43899
Melbin
metformin
Metformin
Metformin (USAN/INN)
Metformin [USAN:INN:BAN]
Metformin HCL
metformin hydrochloride
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
Sandoz Metformin
Siofor
SPBio_001928
STK011633
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
|
|
32 |
|
Omega 3 Fatty Acid |
|
|
|
|
|
33 |
|
Antioxidants |
|
|
|
|
|
34 |
|
Complement C3 |
|
|
|
|
|
35 |
|
carnitine |
|
|
|
|
|
36 |
|
Insulin, Globin Zinc |
|
|
|
|
|
37 |
|
insulin |
|
|
|
|
|
38 |
|
Liver Extracts |
|
|
|
|
|
39 |
|
Arginine |
Investigational, Nutraceutical |
|
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-amino-5-(carbamimidamido)pentanoic acid
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-amino-5-guanidinopentanoic acid
(2S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
|
Arginine
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-arginine
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
R
|
|
Interventional clinical trials:
(show all 25)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients |
Unknown status |
NCT00669435 |
Phase 4 |
Losartan + Simvastatin;Amlodipine + Simvastatin |
2 |
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study |
Completed |
NCT01900015 |
Phase 4 |
Raltegravir;Efavirenz |
3 |
Non-invasive Assessment of Liver Steatosis and Stiffness in HIV-infected Patients With Controlled Attenuation Parameter and Transient Elastography |
Unknown status |
NCT03599882 |
|
|
4 |
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis |
Unknown status |
NCT03386890 |
|
|
5 |
Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis |
Unknown status |
NCT02575625 |
|
|
6 |
Hepaxa Management of Non-Alcoholic Fatty Liver Disease (NAFLD): A Real-world Pilot Study Observing Effects of Nutritional Management With Hepaxa in Subjects With Liver Steatosis |
Unknown status |
NCT03801577 |
|
|
7 |
Growth Hormone Replacement in Adults With Growth Hormone Deficiency (GHD) - The Effect on Liver Fat. |
Completed |
NCT00774579 |
|
|
8 |
Multi Center Survey on Spine and Hip Status in Chinese Population Using Quantitative Computed Tomography (QCT) |
Completed |
NCT01758770 |
|
|
9 |
Usefulness of Controlled Attenuation Parameter (CAP) for the Assessment of Liver Steatosis in Liver Donors |
Completed |
NCT02798861 |
|
|
10 |
Hepatitis C Infection With Liver Steatosis Compared to Hepatitis C Infection Without Liver Steatosis: Is There a Difference in Lipid Peroxidation and Indicators of Inflammation? |
Completed |
NCT00444002 |
|
|
11 |
Effects of Fructose Restriction on Liver Steatosis |
Completed |
NCT03067428 |
|
|
12 |
Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons |
Completed |
NCT00889577 |
|
|
13 |
The Influence of Apolipoprotein C3 Variants on Liver Steatosis and Serum Liver Enzyme Values in Obese Children |
Completed |
NCT01682655 |
|
|
14 |
Effect of Low-glycemic Index Lunches and Dinners Intake on Indicators of Satiety, Metabolic Parameters and Liver Steatosis Degree on Women With Type 2 Diabetes Under Metformin Therapy: Controlled Clinical Trial |
Completed |
NCT03165877 |
|
|
15 |
Influence of Bariatric Endoscopy on Clinical Course of NAFLD |
Recruiting |
NCT04669470 |
|
|
16 |
Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using Vibration Controlled Transient Elastography |
Recruiting |
NCT03778411 |
|
|
17 |
Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes:A Registry and Diagnostic Cohort Study |
Recruiting |
NCT03525769 |
|
|
18 |
Non-Invasive Evaluation of Liver Steatosis, Inflammation and Fibrosis |
Recruiting |
NCT02754037 |
|
|
19 |
The Prevalence of Liver Steatosis, Steatohepatitis, Fibrosis, and Hemosiderosis in Overweight and Obese US Military Dependent Pediatric Patients Using MR Elastography and Quantitative MRI |
Recruiting |
NCT04284371 |
|
|
20 |
Study for the Identification of Participants With Liver Steatosis Who Carry Genetic Variants Associated With Nonalcoholic Fatty Liver Disease (NAFLD) |
Recruiting |
NCT04494360 |
|
|
21 |
Effect of Carnitine Supplementation on Liver Steatosis, Insulin Sensitivity, Plasma Glucose Homeostasis, Skeletal Muscle Metabolism and Energetics: a Pilot Study |
Active, not recruiting |
NCT03439917 |
|
|
22 |
The Liver in the World Trade Center Health Program General Responder Cohort and Controls |
Enrolling by invitation |
NCT03858920 |
|
|
23 |
Effects of Nutritional Supplementation With Amino Acids on Liver Lipid Content, Whole-body Protein Turnover, and Body Composition in Obese Pre-pubertal Children |
Not yet recruiting |
NCT02337894 |
|
|
24 |
Impact of the Hepatitis C Virus Variability on Liver Steatosis |
Terminated |
NCT00843076 |
|
|
25 |
Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment |
Withdrawn |
NCT01987310 |
|
atorvastatin |
|